| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | etoposide | GDSC1000 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | BI-2536 | GDSC1000 | pan-cancer | AAC | 0.15 | 0.003 |
| mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.004 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.1 | 0.004 |
| mRNA | BRD-K84807411 | CTRPv2 | pan-cancer | AAC | 0.22 | 0.004 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | 0.11 | 0.004 |
| mRNA | pac-1 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.005 |
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.005 |
| mRNA | JNJ-26854165 | CTRPv2 | pan-cancer | AAC | 0.098 | 0.005 |